Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2015

01.04.2015 | short review

Beyond R-CHOP: treatment of double hit, tripple hit, MYC + NHL?

verfasst von: MD Michael A. Fridrik

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

Double hit (DH) are defined as MYC and BCL2 or/and BCL6 coexpressing B-cell lymphomas. Morphologically they are found in the diffuse large B-cell lymphoma (DLBCL) or in the group of B-cell lymphoma, unclassifiable, with features between DLBCL and Burkitt lymphoma (BCLU). Approximately 5–10 % of DLBCLs and BCLUs are DH lymphomas according to fluorescence in situ hybridization, the percentage rises to 30 %, if protein overexpression is detected by immunohistochemistry. Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone seems to be insufficient. However, for more intensive regimens and/or high-dose therapy with stem cell rescue conflicting results exist. Clinical trials with novel therapies are urgently needed.
Literatur
1.
Zurück zum Zitat Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–5. CrossRefPubMedCentralPubMed Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–5. CrossRefPubMedCentralPubMed
2.
Zurück zum Zitat Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013–22. CrossRefPubMed Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013–22. CrossRefPubMed
3.
Zurück zum Zitat Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20 + diffuse large B-Cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012;30(36):4462–9. CrossRefPubMedCentralPubMed Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20 + diffuse large B-Cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012;30(36):4462–9. CrossRefPubMedCentralPubMed
4.
Zurück zum Zitat A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987–94. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987–94.
5.
Zurück zum Zitat Zhou Z, Sehn LH, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–42. CrossRefPubMed Zhou Z, Sehn LH, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–42. CrossRefPubMed
6.
Zurück zum Zitat Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–47. CrossRefPubMed Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–47. CrossRefPubMed
7.
Zurück zum Zitat Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82. CrossRefPubMed Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82. CrossRefPubMed
8.
Zurück zum Zitat Ott G, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd H-W, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood. 2010;116(23):4916–25. CrossRefPubMed Ott G, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd H-W, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood. 2010;116(23):4916–25. CrossRefPubMed
9.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008.
10.
Zurück zum Zitat Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma E-J, et al. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319–31. CrossRefPubMed Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma E-J, et al. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319–31. CrossRefPubMed
11.
Zurück zum Zitat Salaverria I, Siebert R. The gray zone between Burkitt’s lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol. 2011;29(14):1835–43. CrossRefPubMed Salaverria I, Siebert R. The gray zone between Burkitt’s lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol. 2011;29(14):1835–43. CrossRefPubMed
12.
Zurück zum Zitat Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol. 2008;21(9):1156–67. CrossRefPubMedCentralPubMed Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol. 2008;21(9):1156–67. CrossRefPubMedCentralPubMed
13.
Zurück zum Zitat Horn H, Ziepert M, Becher C, Barth TFE, Bernd H-W, Feller AC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121(12):2253–63. CrossRefPubMed Horn H, Ziepert M, Becher C, Barth TFE, Bernd H-W, Feller AC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121(12):2253–63. CrossRefPubMed
14.
Zurück zum Zitat Petrich AM, Nabhan C, Smith SM. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches. Cancer. 2014;120:3884–95. CrossRefPubMed Petrich AM, Nabhan C, Smith SM. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches. Cancer. 2014;120:3884–95. CrossRefPubMed
15.
Zurück zum Zitat Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452–9. CrossRefPubMedCentralPubMed Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452–9. CrossRefPubMedCentralPubMed
16.
Zurück zum Zitat Green S, Benedetti J, Crowley J, editors. Clinical trials in oncology. London: Chapman & Hall; 1997. Green S, Benedetti J, Crowley J, editors. Clinical trials in oncology. London: Chapman & Hall; 1997.
17.
Zurück zum Zitat de Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications—a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007;25(7):805–12. CrossRefPubMed de Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications—a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007;25(7):805–12. CrossRefPubMed
18.
Zurück zum Zitat Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-Cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460–7. CrossRefPubMed Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-Cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460–7. CrossRefPubMed
19.
Zurück zum Zitat Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121(20):4021–31. CrossRefPubMedCentralPubMed Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121(20):4021–31. CrossRefPubMedCentralPubMed
20.
Zurück zum Zitat Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166:891–901. doi:10.1111/bjh.12982. CrossRefPubMed Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166:891–901. doi:10.1111/bjh.12982. CrossRefPubMed
21.
Zurück zum Zitat Gandhi M, Petrich AM, Cassaday RD, Press OW, Shah K, Whyman J, et al., editors. Impact of induction regimen and consolidative stem cell transplantation in patients with double hit lymphoma (DHL): a large multicenter retrospective analysis. ASH (Annual Meeting Abstracts). 2013. Gandhi M, Petrich AM, Cassaday RD, Press OW, Shah K, Whyman J, et al., editors. Impact of induction regimen and consolidative stem cell transplantation in patients with double hit lymphoma (DHL): a large multicenter retrospective analysis. ASH (Annual Meeting Abstracts). 2013.
22.
Zurück zum Zitat Macpherson N, Lesack D, Klasa R, Horsman D, Connors JM, Barnett M, et al. Small noncleaved, non-Burkitt’s (Burkitt-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol. 1999;17(5):1558–67. PubMed Macpherson N, Lesack D, Klasa R, Horsman D, Connors JM, Barnett M, et al. Small noncleaved, non-Burkitt’s (Burkitt-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol. 1999;17(5):1558–67. PubMed
23.
Zurück zum Zitat Kanungo A, Medeiros LJ, Abruzzo LV, Lin P. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol. 2006;19(1):25–33. CrossRefPubMed Kanungo A, Medeiros LJ, Abruzzo LV, Lin P. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol. 2006;19(1):25–33. CrossRefPubMed
24.
Zurück zum Zitat Le Gouill S, Talmant P, Touzeau C, Moreau A, Garand R, Juge-Morineau N, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007;92(10):1335–42. CrossRefPubMed Le Gouill S, Talmant P, Touzeau C, Moreau A, Garand R, Juge-Morineau N, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007;92(10):1335–42. CrossRefPubMed
25.
Zurück zum Zitat Niitsu N, Okamoto M, Miura I, Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia. 2009;23(4):777–83. CrossRefPubMed Niitsu N, Okamoto M, Miura I, Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia. 2009;23(4):777–83. CrossRefPubMed
26.
Zurück zum Zitat Tomita N, Tokunaka M, Nakamura N, Takeuchi K, Koike J, Motomura S, et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica. 2009;94:935–43. CrossRefPubMedCentralPubMed Tomita N, Tokunaka M, Nakamura N, Takeuchi K, Koike J, Motomura S, et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica. 2009;94:935–43. CrossRefPubMedCentralPubMed
27.
Zurück zum Zitat Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34(3):327–40. CrossRefPubMedCentralPubMed Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol. 2010;34(3):327–40. CrossRefPubMedCentralPubMed
28.
Zurück zum Zitat Li S, Lin P, Fayad LE, Lennon PA, Miranda RN, Yin CC, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol. 2012;25(1):145–56. CrossRefPubMed Li S, Lin P, Fayad LE, Lennon PA, Miranda RN, Yin CC, et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol. 2012;25(1):145–56. CrossRefPubMed
29.
Zurück zum Zitat Pedersen MØ, Gang AO, Poulsen TS, Knudsen H, Lauritzen AF, Nielsen SL, Gang UO, et al. Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma—a single centre’s experience. Eur J Haematol. 2012;89:63–71. doi: 10.1111/j.1600-0609.2012.01787.x. CrossRefPubMed Pedersen MØ, Gang AO, Poulsen TS, Knudsen H, Lauritzen AF, Nielsen SL, Gang UO, et al. Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma—a single centre’s experience. Eur J Haematol. 2012;89:63–71. doi: 10.1111/j.1600-0609.2012.01787.x. CrossRefPubMed
30.
Zurück zum Zitat Cohen JB, Geyer SM, Lozanski G, Zhao W, Heerema NA, Hall NC, Nagar VA, et al. Complete response to induction therapy in patients with MYC-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival. Cancer. 2014;120(11):1677–85. CrossRefPubMedCentralPubMed Cohen JB, Geyer SM, Lozanski G, Zhao W, Heerema NA, Hall NC, Nagar VA, et al. Complete response to induction therapy in patients with MYC-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival. Cancer. 2014;120(11):1677–85. CrossRefPubMedCentralPubMed
31.
Zurück zum Zitat Pillai RK, Sathanoori M, Van Oss SB, Swerdlow SH. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. Am J Surg Pathol. 2013;37(3):323–31. doi:10.1097/PAS.0b013e31826cebad. CrossRefPubMed Pillai RK, Sathanoori M, Van Oss SB, Swerdlow SH. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. Am J Surg Pathol. 2013;37(3):323–31. doi:10.1097/PAS.0b013e31826cebad. CrossRefPubMed
32.
Zurück zum Zitat Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, Liu WM, et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica. 2013;98: 255–63. doi:10.3324/haematol.2012.066209. CrossRefPubMedCentralPubMed Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, Liu WM, et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica. 2013;98: 255–63. doi:10.3324/haematol.2012.066209. CrossRefPubMedCentralPubMed
33.
Zurück zum Zitat Landsburg DJ, Nasta SD, Svoboda J, Morrissette JJ, Schuster SJ. ‘Double-Hit’ cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. Br J Haematol. 2014;166:369–74. CrossRefPubMed Landsburg DJ, Nasta SD, Svoboda J, Morrissette JJ, Schuster SJ. ‘Double-Hit’ cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. Br J Haematol. 2014;166:369–74. CrossRefPubMed
34.
Zurück zum Zitat Aukema SM, Kreuz M, Kohler CW, Rosolowski M, Hasenclever D, Hummel M, Küppers R, et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica. 2014;99(4):726–35. doi:10.3324/haematol.2013.091827. CrossRefPubMedCentralPubMed Aukema SM, Kreuz M, Kohler CW, Rosolowski M, Hasenclever D, Hummel M, Küppers R, et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica. 2014;99(4):726–35. doi:10.3324/haematol.2013.091827. CrossRefPubMedCentralPubMed
35.
Zurück zum Zitat Jaglal MV, Peker D, Tao J, Cultrera JL. Double and triple hit diffuse large B-cell lymphomas and first line therapy. ASH Annual Meeting Abstracts. 2012;120(21):4885. Jaglal MV, Peker D, Tao J, Cultrera JL. Double and triple hit diffuse large B-cell lymphomas and first line therapy. ASH Annual Meeting Abstracts. 2012;120(21):4885.
36.
Zurück zum Zitat Perry AM, Alvarado-Bernal Y, Laurini JA, Smith LM, Slack GW, Tan KL, et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol. 2014;165(3):382–91. CrossRefPubMed Perry AM, Alvarado-Bernal Y, Laurini JA, Smith LM, Slack GW, Tan KL, et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol. 2014;165(3):382–91. CrossRefPubMed
Metadaten
Titel
Beyond R-CHOP: treatment of double hit, tripple hit, MYC + NHL?
verfasst von
MD Michael A. Fridrik
Publikationsdatum
01.04.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0200-1

Weitere Artikel der Ausgabe 1/2015

memo - Magazine of European Medical Oncology 1/2015 Zur Ausgabe